Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARALU: Pluvicto added to darolutamide plus ADT in metastatic hormone-sensitive prostate cancer
2026-525520-20-00Phase 2Authorised
- Sponsor
- Universitätsklinikum Freiburg
- Start
- Oct 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lutetium lu 177 vipivotide tetraxetan in prostate cancer (PCa) (2 arms), sponsored by Universitätsklinikum Freiburg. Primary endpoint: PSA response rate until month 12. Planned start Oct 2026; status: authorised.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2026-525520-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525520-20-00.